SENATE No. 502

The Commonwealth of Massachusetts

PRESENTED BY:

Anne M. Gobi

To the Honorable Senate and House of Representatives of the Commonwealth of Massachusetts in General Court assembled:

The undersigned legislators and/or citizens respectfully petition for the adoption of the accompanying bill:

An Act relative to Lyme Disease treatment coverage.

PETITION OF:

NAME:	DISTRICT/ADDRESS:
Anne M. Gobi	Worcester, Hampden, Hampshire and
	Middlesex
Harriette L. Chandler	First Worcester
Marc R. Pacheco	First Plymouth and Bristol
Brian A. Joyce	Norfolk, Bristol and Plymouth
Kenneth J. Donnelly	Fourth Middlesex
William N. Brownsberger	Second Suffolk and Middlesex
James B. Eldridge	Middlesex and Worcester
Thomas M. McGee	Third Essex
Sal N. DiDomenico	Middlesex and Suffolk
Joan B. Lovely	Second Essex
John F. Keenan	Norfolk and Plymouth
Michael O. Moore	Second Worcester
Daniel A. Wolf	Cape and Islands
Michael J. Rodrigues	First Bristol and Plymouth
James E. Timilty	Bristol and Norfolk
Michael F. Rush	Norfolk and Suffolk
Eileen M. Donoghue	First Middlesex

Jennifer L. Flanagan	Worcester and Middlesex
Barbara L'Italien	Second Essex and Middlesex
Jason M. Lewis	Fifth Middlesex
Eric P. Lesser	First Hampden and Hampshire
Robert L. Hedlund	Plymouth and Norfolk
Richard J. Ross	Norfolk, Bristol and Middlesex
Donald F. Humason, Jr.	Second Hampden and Hampshire
Ryan C. Fattman	Worcester and Norfolk
Gailanne M. Cariddi	1st Berkshire
Thomas J. Calter	12th Plymouth
Angelo J. Puppolo, Jr.	12th Hampden
Josh S. Cutler	6th Plymouth
Paul K. Frost	7th Worcester
Jonathan D. Zlotnik	2nd Worcester
Ann-Margaret Ferrante	5th Essex
Sheila C. Harrington	1st Middlesex
Danielle W. Gregoire	4th Middlesex
Dennis A. Rosa	4th Worcester
Timothy R. Madden	Barnstable, Dukes and Nantucket
Cory Atkins	14th Middlesex
Thomas M. Stanley	9th Middlesex
Keiko M. Orrall	12th Bristol
Tricia Farley-Bouvier	3rd Berkshire
Ruth B. Balser	12th Middlesex
Carolyn C. Dykema	8th Middlesex
Mary S. Keefe	15th Worcester
John J. Lawn, Jr.	10th Middlesex
Edward F. Coppinger	10th Suffolk
Paul A. Schmid, III	8th Bristol
Kathleen O'Connor Ives	First Essex
Sean Garballey	23rd Middlesex
Steven S. Howitt	4th Bristol
Susan Williams Gifford	2nd Plymouth
Todd M. Smola	1st Hampden
Leah Cole	12th Essex
Kevin J. Kuros	8th Worcester
Nicholas A. Boldyga	3rd Hampden
David T. Vieira	3rd Barnstable
Paul R. Heroux	2nd Bristol

James Arciero	2nd Middlesex
Donald R. Berthiaume, Jr.	5th Worcester
Steven Ultrino	33rd Middlesex
Chris Walsh	6th Middlesex

SENATE No. 502

By Ms. Gobi, a petition (accompanied by bill, Senate, No. 502) of Anne M. Gobi, Harriette L. Chandler, Marc R. Pacheco, Brian A. Joyce and other members of the General Court for legislation relative to Lyme Disease treatment coverage. Financial Services.

The Commonwealth of Massachusetts

In the One Hundred and Eighty-Ninth General Court (2015-2016)

An Act relative to Lyme Disease treatment coverage.

Be it enacted by the Senate and House of Representatives in General Court assembled, and by the authority of the same, as follows:

- SECTION 1. Chapter 175 of the General Laws is hereby amended by inserting after
- 2 section 47DD, the following section:
- 3 Section 47EE. (A) For the purposes of this Section, the terms "Lyme disease" and "long-
- 4 term antibiotic therapy" are given the same definition as provided in M.G.L. Chapter 112,
- 5 Section 12DD.
- 6 (B) Any policy, contract, agreement, plan or certificate of insurance issued, delivered or
- 7 renewed within the commonwealth that provides medical expense coverage shall provide
- 8 coverage for long-term antibiotic therapy of Lyme disease when determined to be medically
- 9 necessary and ordered by a licensed physician after making a thorough evaluation of the patient's
- 10 symptoms, diagnostic test results, or response to treatment. Long-term antibiotic therapy
- 11 otherwise eligible for benefits pursuant to this section shall not be denied solely because such
- 12 treatment may be characterized as unproven, experimental, or investigational in nature.

- SECTION 2. Chapter 176A of the General Laws is hereby amended by inserting after section 8FF the following section:-
- Section 8GG. Any contract between a subscriber and the corporation under an individual or group hospital service plan which is delivered, issued or renewed within the commonwealth shall provide coverage for long-term antibiotic therapy of Lyme disease when determined to be medically necessary and ordered by a licensed physician after making a thorough evaluation of the patient's symptoms, diagnostic test results or response to treatment. Treatment otherwise eligible for benefits pursuant to this section shall not be denied solely because such treatment may be characterized as unproven, experimental, or investigational in nature.
- SECTION 4. Chapter 176B of the General Laws is hereby amended by inserting after section 4FF, the following section:-
- Section 4GG. Any subscription certificate under an individual or group medical service agreement delivered, issued, or renewed within the commonwealth shall provide coverage for long-term antibiotic therapy of Lyme disease when determined to be medically necessary and ordered by a licensed physician after making a thorough evaluation of the patient's symptoms, diagnostic test results or response to treatment. Treatment otherwise eligible for benefits pursuant to this section shall not be denied solely because such treatment may be characterized as unproven, experimental, or investigational in nature.
- SECTION 5. Chapter 176G of the General Laws is hereby amended by inserting after section 4X the following section:-
- Section 4Y. Any individual or group health maintenance contract shall provide coverage for long-term antibiotic therapy of Lyme disease when determined to be medically necessary and

- 35 ordered by a licensed physician after making a thorough evaluation of the patient's symptoms,
- 36 diagnostic test results or response to treatment. Treatment otherwise eligible for benefits
- 37 pursuant to this section shall not be denied solely because such treatment may be characterized
- 38 as unproven, experimental, or investigational in nature.